Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Ravandi F, Cloos J, Buccisano F, Dillon R, Döhner K, Freeman SD, Hourigan CS, Ossenkoppele GJ, Roboz GJ, Subklewe M, Thiede C, Arnhardt I, Valk PJM, Venditti A, Wei AH, Walter RB, Heuser M.
Ravandi F, et al. Among authors: hourigan cs.
Am J Hematol. 2023 Dec;98(12):1847-1855. doi: 10.1002/ajh.27087. Epub 2023 Sep 6.
Am J Hematol. 2023.
PMID: 37671649